<DOC>
	<DOCNO>NCT00228592</DOCNO>
	<brief_summary>The purpose study compare use HepeX-B versus HBIg , two anti-viral drug , patient receive liver transplant due liver failure cause Hepatitis B infection . Patients evaluate 6 month 1.5 year period evaluate whether drug prevent Hepatitis B virus infect new liver .</brief_summary>
	<brief_title>HepeX-B Post Hepatic Allografts Treatment End Stage Liver Disease Due Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female patient 18 year age old , Patients least 6 month post first orthotopic liver transplantation ( live cadaveric donor ) treatment endstage liver disease due HBV infection , Patients receive HBIg since transplantation stable regimen ( i.e. , dose frequency ) least 3 month immediately precede study entry ( Day 1 ) , Patients receive treatment inhibitor HBV polymerase least 3 month immediately precede study entry ( Day 1 ) , Patients undetectable HBsAg HBV DNA concentration two consecutive test least 1 week apart screen period , Female patient childbearing potential , male whose partner woman childbearing potential , require use adequate contraception , Patients able provide write informed consent . Patients successfully complete initial 20week treatment core trial eligible 52week extension phase . Women pregnant breastfeeding , Patients receive another organ transplant require immunosuppression , Patients coinfected hepatitis delta virus ( HDV ) , hepatitis C virus ( HCV ) and/or human immunodeficiency virus ( HIV ) , Patients clinical condition disease , , judgment investigator , would place patient undue risk , interfere study participation , confound result study , and/or Patients participate clinical study 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>